Clinical Trials

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07400523 2026-04-17

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

446 enrolled

Breast Neoplasms

NCT07085767 2026-04-16

OPERA-02

1,000 enrolled

Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

500 enrolled

Phase 3 Not yet recruiting

Advanced Breast Cancer

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

1,978 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Phase 3 Not yet recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07340658 2026-04-02

SIE-3

300 enrolled

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 3 FDA

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

1,056 enrolled

HR+/HER2- Breast Cancer

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

500 enrolled

Breast Neoplasms

NCT07237256 2026-03-16

NoLEEta

3,902 enrolled

Breast Neoplasms

NCT06760637 2026-03-02

FourLight-3

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04055493 2025-08-26

ADAPTcycle

1,684 enrolled

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Breast Neoplasms

NCT01958021 2025-03-07

MONALEESA-2

668 enrolled 15 charts

Breast Neoplasms

NCT03439046 2024-08-01

BioItaLEE

287 enrolled

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT02278120 2024-03-12

MONALEESA-7

672 enrolled 16 charts 1 FDA

Advanced Metastatic Breast Cancer

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT02941926 2023-10-24

COMPLEEMENT-1

3,246 enrolled 11 charts

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

41 enrolled

Breast Neoplasms

NCT03096847 2021-10-11

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

502 enrolled 20 charts

Breast Neoplasms, Osteitis Deformans

NCT03905343 2021-06-16

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3 Terminated

25 enrolled

Breast Neoplasms

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3 Terminated

8 enrolled 4 charts

BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT03081234 2018-03-15

EarLEE-2

Phase 3 Withdrawn